English

Biohit's financial information in 2012

Report this content

Biohit Oyj
Company Announcement
14.12.2011 05:21 pm

Biohit will release its financial statement for 2011 on Wednesday 29 February 2012, at 9:30 AM.

Biohit Oyj’s Annual General Meeting has been planned for Wednesday, 11 April 2012, 3:00 PM. The Board of Directors will call the General Meeting at a later date.

The company will publish three interim reports in 2012, based on the following schedule:

  • The interim report for period January - March 2012, on Thursday 26 April 2012, 9:30 AM.
  • The interim report for period January - June 2012, on Thursday 16 August 2012, 9:30 AM.
  • The interim report for period January - September 2012, on Thursday 25 October 2012, 9:30 AM.

The published economic reports and other stock exchange releases will be available on Biohit's website at www.biohit.com/investors. The website also contains an online form for ordering  electronic copies, which will be e-mailed to you.

 

For further details, contact:

Osmo Suovaniemi
MD, Ph.D, Professor
Chairman of the Board of Directors
Tel. +358 40 745 5605
osmo.suovaniemi@biohit.com

    

Distribution:

NASDAQ OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.com


About Biohit

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission crystallises in its motto “Innovating for Health”. The company assumes social responsibility by producing innovations, new technologies and analysis systems for use in medicine, research institutions and industry. These products help to promote research and diagnostics, while improving quality of life by preventing disease, human suffering and financial loss. Biohit also seeks to innovate and develop the marketing and availability of its products and services, in order to ensure its profitable growth and ability to pay dividends.

Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations. These can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.

Biohit's products include analysis systems for the prevention and early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic stomach.

Biohit employs around 35 people. The company is headquartered in Helsinki, Finland and has a subsidiary in the UK.  Since 1999, Biohit’s Series B share (BIOBV) has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group and is traded under the code BIOBV (www.biohit.com/investors).

 

Read more at www.biohit.com.

Subscribe